clinical trial | Q30612 |
P3098 | ClinicalTrials.gov ID | NCT00303485 |
P6099 | clinical trial phase | phase IV clinical trial | Q42825046 |
P17 | country | United States of America | Q30 |
P582 | end time | 2007-06-01 | |
P131 | located in the administrative territorial entity | Puerto Rico | Q1183 |
P1050 | medical condition | osteoporosis | Q165328 |
P2899 | minimum age | 65 | |
P1132 | number of participants | 67 | |
P4844 | research intervention | calcium oxalate | Q412399 |
(5R)-24,25-Dihydroxyvitamin D | Q27161510 | ||
ibandronic acid | Q166825 | ||
P859 | sponsor | Hoffmann-La Roche | Q212646 |
P580 | start time | 2006-02-01 | |
P8363 | study type | interventional study | Q78089383 |
P1476 | title | A Randomized, Double-blind, Placebo-controlled Study to Determine Time to Onset of Suppression of the Bone Resorption Marker sCTX With Once Monthly Ibandronate in the Treatment of Postmenopausal Osteoporosis |